An interventional study of GI Genius-assisted diagnostic colonoscopy and Diagnostic Colonoscopy in Colonic Polyp, Colorectal Polyp and Colorectal Adenoma, sponsored by South Tyneside and Sunderland NHS Foundation Trust. Completed at 10 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by South Tyneside and Sunderland NHS Foundation Trust · Not applicable, Interventional, and Diagnostic
COLO-DETECT is a clinical trial to evaluate whether an Artificial Intelligence device ("GI Genius", manufactured by Medtronic) can identify more polyps (pre-cancerous growths of the bowel lining) during colonoscopy (large bowel camera test) than during colonoscopy without it.
Colorectal cancer is common, affecting 1 in 15 men and 1 in 18 women in the UK in their lifetime. Many colorectal cancers develop from polyps via the adenoma-carcinoma sequence: there is a pre-cancerous stage (adenoma) during which it is possible to remove the polyp and therefore prevent it from progressing to colorectal cancer. The gold standard tool for doing this is colonoscopy. However, colonoscopy does not pick up all polyps, particularly flat polyps.
Missed polyps can result in colorectal cancer, so it is imperative to detect and remove as many polyps as possible. Many different interventions have been introduced to improve polyp detection, the most recent of which is artificial intelligence devices. GI Genius is an artificial intelligence device which integrates with existing colonoscopy equipment and analyses the video feed from the colonoscope camera in real time. Any areas that may represent an abnormality are then highlighted (without any lag) within a green box, alerting the colonoscopist to its presence. The potential abnormality can then be assessed more closely by the colonoscopist to decide whether it needs to be removed or not.
COLO-DETECT is a 2-arm, prospective, randomised controlled trial to assess whether GI Genius is able to detect more polyps (specifically, adenomas) during colonoscopy than standard colonoscopy without GI Genius. The primary outcome will be the mean number of adenomas per procedure (MAP) and the key secondary outcome will be the proportion of colonoscopies in which one or more adenomas is detected (Adenoma Detection Rate - ADR). These are both important quality markers for colonoscopy; the study will be powered to detect a clinically meaningful difference in ADR, which will by default detect a meaningful difference in MAP as the sample size required for ADR is larger.
In addition to measuring the effect of GI Genius on polyp detection, COLO-DETECT will provide a health economics analysis concerning the use of GI Genius, perform long-term passive follow-up to examine for future outcomes related to colorectal polyps and colorectal cancer, and perform additional nested studies (subject to ethical approval) that examine the effect upon users (for example through a visual scanning study) and their experience of using the GI Genius.
657 studies on the registry are indexed under Adenoma; 98 are open to participants now.
This study's enrollment of 2,032 is above the median of 250 across 412 interventional studies indexed under Adenoma.
Browse Adenoma studies →South Tyneside and Sunderland NHS Foundation Trust is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients attending for colonoscopy
Exclusion Criteria:
In the GGC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure, except that at some point prior to commencing withdrawal of the colonoscope, a member of the endoscopy staff will turn on the GI Genius machine. This will remain operational from the time it is switched on until the end of the procedure.
Device: GI Genius-assisted diagnostic colonoscopy
In the SC arm, participants will undergo colonoscopy as per standard care for the unit where they are having their procedure.
Diagnostic Test: Diagnostic Colonoscopy
Participants will undergo diagnostic colonoscopy, which will be identical to the normal standard of care at the unit where they are undergoing their procedure, except that GI Genius will be turned on during the procedure.
Diagnostic colonoscopy will be performed as per the standard of care for the unit where the patient is having their procedure.
Number of adenomas per participant detected at colonoscopy as indicated by the Mean Number of Adenomas per Procedure (MAP)
The number of adenomas identified during each colonoscopy will be summed and divided by the total number of colonoscopies performed. MAP is usually expressed as a number to one decimal place (e.g. 1.2).
Time frame: The number of adenomas detected in each procedure will be counted at 14 days post-procedure
Proportion of participants in whom at least one adenoma is detected at colonoscopy, as indicated by the Adenoma Detection Rate (ADR)
Whether or not at least one adenoma is detected at colonoscopy will be determined for each participant. The number of colonoscopies where one or more adenomas is identified will be divided by the total number of colonoscopies to give the ADR. ADR is usually expressed as a percentage.
Time frame: The presence or absence of any adenomas will be determined at 14 days post-procedure
Number of adenomas per participant detected at colonoscopy in the 'screening' participant population, as indicated by MAP for that participant population.
The number of adenomas identified during each colonoscopy within the 'screening' participant population will be summed and divided by the total number of colonoscopies in that participant population. The MAP for the 'screening' participant population within each study arm will be compared
Time frame: The number of adenomas detected will be counted at 14 days post-procedure
Number of adenomas per participant detected at colonoscopy in the 'symptomatic' participant population, as indicated by MAP for that participant population
The number of adenomas identified during each colonoscopy within the 'symptomatic' participant population will be summed and divided by the total number of colonoscopies in that participant population to calculate MAP. The MAP for the 'symptomatic' participant population within each study arm will be compared
Time frame: The number of adenomas detected will be counted at 14 days post-procedure
Proportion of participants in the 'screening' participant population in whom at least one adenoma is detected at colonoscopy, as indicated by ADR for that participant population
Whether or not at least one adenoma is detected at colonoscopy will be determined for each participant within the 'screening' participant population. The number of colonoscopies where one or more adenomas is identified will be divided by the total number of colonoscopies in that participant population to calculate ADR. The ADR for the 'screening' participant population within each study arm will be compared
Time frame: The presence or absence of any adenomas will be determined at 14 days post-procedure
Proportion of participants in the 'symptomatic' participant population in whom at least one adenoma is detected at colonoscopy, as indicated by ADR for that participant population
Whether or not at least one adenoma is detected at colonoscopy will be determined for each participant within the 'symptomatic' participant population. The number of colonoscopies where one or more adenomas is identified will be divided by the total number of colonoscopies in that participant population to calculate ADR. The ADR for the 'symptomatic' participant population within each study arm will be compared
Time frame: The presence or absence of any adenomas will be determined at 14 days post-procedure
Number of polyps per participant detected at colonoscopy, as indicated by the Mean number of Polyps per Procedure (MPP)
The total number of polyps detected during each colonoscopy will be summed, and divided by the total number of colonoscopies, to calculate MPP. MPP is usually expressed as a number to one decimal place.
Time frame: Total number of polyps detected at colonoscopy will be determined at the end of the procedure
Number of polyps per participant detected at colonoscopy in the 'screening' participant population, as indicated by the Mean number of Polyps per Procedure (MPP)
The total number of polyps detected during colonoscopy for each participant within the 'screening' participant population. will be summed, and divided by the total number of colonoscopies in that participant population, to calculate MPP. MPP is usually expressed as a number to one decimal place.
Time frame: Total number of polyps detected at colonoscopy will be determined at the end of the procedure
Number of polyps per participant detected at colonoscopy in the 'symptomatic' participant population,as indicated by the Mean number of Polyps per Procedure (MPP)
The total number of polyps detected during colonoscopy for each participant within the 'symptomatic' participant population will be summed, and divided by the total number of colonoscopies in that participant population, to calculate MPP. MPP is usually expressed as a number to one decimal place.
Time frame: Total number of polyps detected at colonoscopy will be determined at the end of the procedure
Proportion of participants in whom at least one polyp is detected at colonoscopy, as indicated by Polyp Detection Rate (PDR)
Whether or not at least one polyp is detected at colonoscopy will be determined for each participant. The number of colonoscopies where one or more polyps is detected will be divided by the total number of colonoscopies in that participant population to calculate PDR, which is normally expressed as a percentage.
Time frame: The presence or absence of at least one polyp will be determined at the end of the procedure
Proportion of participants in the 'screening' participant population in whom at least one polyp is detected at colonoscopy, as indicated by Polyp Detection Rate (PDR)
Whether or not at least one polyp is detected at colonoscopy will be determined for each participant within the 'screening' participant population. The number of colonoscopies where one or more polyps is identified will be divided by the total number of colonoscopies in that participant population to calculate PDR, which is normally expressed as a percentage.
Time frame: The presence or absence of at least one polyp will be determined at the end of the procedure
Proportion of participants in the 'symptomatic' participant population in whom at least one polyp is detected at colonoscopy, as indicated by Polyp Detection Rate (PDR)
Whether or not at least one polyp is detected at colonoscopy will be determined for each participant within the 'symptomatic' participant population. The number of colonoscopies where one or more polyps is identified will be divided by the total number of colonoscopies in that participant population to calculate PDR, which is normally expressed as a percentage.
Time frame: The presence or absence of at least one polyp will be determined at the end of the procedure
Polyp characteristics and location
The location, size, and morphology of the polyps identified (and histology if retrieved) in each study arm will be compared. This will also be analysed for both the screening and symptomatic participant populations in each study arm.
Time frame: Assessed over duration of colonoscopy procedure and at time of 14 day post-colonoscopy review (once histology is known)
Sessile Serrated Polyp (SSP) detection rate
The number of colonoscopies in each study arm in which one or more SSPs is identified, divided by the total number of colonoscopies in each arm. This will also be analysed for both the screening and symptomatic participant populations in each study arm.
Time frame: SSP Detection Rate will be calculated at the time of study completion, expected to be 18 months
Colorectal Cancer (CRC) detection rate
The number of CRCs detected in each study arm divided by the total number of colonoscopies in each arm. This will include polyps removed and later found to cancerous on histology and lesions felt to be cancerous at the time of colonoscopy. This will also be analysed for both the screening and symptomatic participant populations in each study arm.
Time frame: CRC Detection Rate will be calculated at the time of study completion, expected to be 18 months
Advanced Adenoma (AA) detection rate
The number of AAs detected in each study arm divided by the total number of colonoscopies in each arm. This will also be analysed for both the screening and symptomatic participant populations in each study arm.
Time frame: AA Detection Rate will be calculated at the time of study completion, expected to be 18 months
Caecal Intubation Rate
Caecal intubation rate (the proportion of colonoscopies in which the colonoscope reaches the furthest extent of the colon) will be compared between the study arms to assess for non-inferiority
Time frame: Caecal Intubation Rate will be calculated at the time of study completion, expected to be 18 months
Insertion time to caecum
Insertion time to caecum (time taken to reach the furthest point of the large bowel) will be compared between the study arms to assess for non-inferiority
Time frame: Measured during colonoscopy within the study.
Total Procedure Time
Total time required to perform the colonoscopy will be compared between the study arms to assess for non-inferiority
Time frame: Measured during colonoscopy within the study.
Total Withdrawal Time (in absence of polyps)
Total withdrawal time (time taken to remove the colonoscope from the furthest point of the colon) in the absence of any polyps will be compared between the study arms to assess for non-inferiority
Time frame: Measured during colonoscopy within the study.
Colonoscopist-assessed patient comfort score
Colonoscopist-assessed patient comfort scores will be compared between the study arms to assess for non-inferiority
Time frame: Measured during colonoscopy within the study.
Nurse-assessed patient comfort score
Nurse-assessed patient comfort scores will be compared between the study arms to assess for non-inferiority
Time frame: Measured during colonoscopy within the study.
Patient-Reported Experience
A validated Patient-Reported Experience Measure (Newcastle ENDOPREM) will be used to compare patient experience of colonoscopy between study arms
Time frame: Assessed one day after the procedure
Patient-Reported Health-Related Quality of Life
The EuroQoL EQ-5D-5L (validated quality of life questionnaire) will be used to compare patient-reported health-related quality of life, between study arms
Time frame: Assessed one day after the procedure
Projected future endoscopy workload
The need for further colonoscopy for each participant is determined by the findings at the index colonoscopy, according to national guidelines on polyp surveillance. This may differ between study arms if more polyps are identified in one arm.
Time frame: Assessed immediately after colonoscopy
MAP according to BCSP status of colonoscopist
Some colonoscopists partake in the national Bowel Cancer Screening Programme (BCSP) and some do not. MAP will be analysed by colonoscopist status within each study arm.
Time frame: At the time of 14-day review
ADR according to BCSP status of colonoscopist
Some colonoscopists partake in the national Bowel Cancer Screening Programme (BCSP) and some do not. ADR will be analysed by colonoscopist status within each study arm.
Time frame: At the time of 14-day review
Change in number of adenomas detected per colonoscopy, for each colonoscopist, over the course of the study, as indicated by MAP
MAP for the first 20 percent of participants will be compared to MAP for the last 20 percent of participants scoped by each participating colonoscopist, to assess for change over the course of the study.
Time frame: At the time of 14-day review
Change in proportion of participants in whom at least one adenoma is detected during colonoscopy, for each colonoscopist, over the course of the study, as indicated by ADR.
ADR for the first 20 percent of participants will be compared to ADR for the last 20 percent of participants scoped by each participating colonoscopist, to assess for change over the course of the study.
Time frame: At the time of 14-day review
Change in number of adenomas detected per participant, for each participating colonoscopist, from pre-study to intra-study (SC arm only)
MAP may vary from baseline, even in the control arm due to a contamination or learning effect; comparing baseline values to those during the study assesses for this effect.
Time frame: At the time of 14-day review
Proportion of participants in whom at least one adenoma is detected during colonoscopy, for each participating colonoscopist, from pre-study to intra-study (SC arm only)
ADR may vary from baseline, even in the control arm due to a contamination or learning effect; comparing baseline values to those during the study assesses for this effect.
Time frame: At the time of 14-day review
Cost-effectiveness of GGC versus SC
Equipment, staff, histology, unplanned admission, and other related costs will be calculated and used to determine cost-effectiveness of GGC versus SC.
Time frame: Costs associated with each participant's procedure and care will be calculated at time of 14-day review
Number of adenomas per participant detected at colonoscopy, amongst colonoscopists not participating in the study, as indicated by MAP
MAP values over the duration of the study, for colonoscopists not participating in the study but performing colonoscopy at study sites, will assist with baseline comparisons. These data are reported by endoscopy units as part of the normal endoscopy quality assurance programme.
Time frame: At time of 14-day review
Proportion of participants in whom at least one adenoma is detected at colonoscopy, by colonoscopists not participating in the study, as indicated by ADR
ADR values over the duration of the study, for colonoscopists not participating in the study but performing colonoscopy at study sites, will assist with baseline comparisons. These data are reported by endoscopy units as part of the normal endoscopy quality assurance programme.
Time frame: At time of 14-day review
Plan to share: No
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
South Tyneside and Sunderland NHS Foundation Trust